Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.

Zhe LiangQi ChenFei YangXianliang YanXuehui ZhangXue ChenFang FangQuanming Zhao

Published in: Cardiovascular drugs and therapy (2020)

Evolocumab in patients with MI was not cost-effective based on the price in 2019 in China; however, treatment with evolocumab was more favorable in MI patients with FH.

Keyphrases

healthcare
low density lipoprotein
heart failure
left ventricular
replacement therapy
health information
health insurance